Open AccessRapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report
Author(s) -
Ben Li,
Guanwu Li,
Xue Lin,
Yueying Chen
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i19.4527
Subject(s) - medicine , tofacitinib , pustulosis , palmoplantar pustulosis , hyperostosis , sapho syndrome , osteitis , dermatology , refractory (planetary science) , janus kinase inhibitor , synovitis , acne , gastroenterology , surgery , arthritis , osteomyelitis , psoriasis , rheumatoid arthritis , physics , astrobiology
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoinflammatory disease for which clinical treatment has not been standardized. Janus kinase (JAK) inhibitors represent a novel therapeutic option for rheumatoid arthritis, psoriatic arthritis, and some other autoinflammatory diseases. However, the clinical utility of JAK inhibitors in treating SAPHO syndrome has not been thoroughly investigated. In this study, we describe a patient with SAPHO syndrome who failed to respond to conventional treatment but demonstrated a remarkable and rapid response to the JAK inhibitor tofacitinib.